The first new Toyota HiLux in a decade brings plenty to the table on the road and in the showroom. Is it enough?
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results from new post hoc analyses of the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback